Geode Capital Management LLC Has $7.39 Million Stake in Heron Therapeutics, Inc. $HRTX

Geode Capital Management LLC raised its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 14.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,566,813 shares of the biotechnology company’s stock after buying an additional 453,085 shares during the quarter. Geode Capital Management LLC’s holdings in Heron Therapeutics were worth $7,385,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. R Squared Ltd bought a new position in Heron Therapeutics during the 2nd quarter worth approximately $26,000. ProShare Advisors LLC increased its stake in Heron Therapeutics by 23.4% in the second quarter. ProShare Advisors LLC now owns 31,368 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 5,953 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in Heron Therapeutics in the second quarter worth $103,000. Deutsche Bank AG boosted its position in shares of Heron Therapeutics by 43.2% during the first quarter. Deutsche Bank AG now owns 85,610 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 25,824 shares in the last quarter. Finally, Headlands Technologies LLC grew its holdings in shares of Heron Therapeutics by 260.5% in the 1st quarter. Headlands Technologies LLC now owns 92,558 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 66,886 shares during the period. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Stock Performance

Shares of Heron Therapeutics stock opened at $1.31 on Friday. The company has a debt-to-equity ratio of 19.89, a current ratio of 2.56 and a quick ratio of 1.78. The firm has a market cap of $240.20 million, a price-to-earnings ratio of -14.55 and a beta of 1.34. The stock’s 50-day moving average is $1.20 and its 200-day moving average is $1.54. Heron Therapeutics, Inc. has a one year low of $1.00 and a one year high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.03). The company had revenue of $38.21 million during the quarter, compared to analyst estimates of $39.03 million. Equities analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on HRTX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Needham & Company LLC cut their price objective on Heron Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, August 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Tuesday, November 4th. Finally, Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Heron Therapeutics has a consensus rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.